Clinical Trial: A Clinical Study on the Efficacy and Safety of the Combination of Limertinib and Bevacizumab Versus Limertinib as First-line Treatment for NSCLC.

U.S., May 22 -- ClinicalTrials.gov registry received information related to the study (NCT06982924) titled 'A Clinical Study on the Efficacy and Safety of the Combination of Limertinib and Bevacizumab Versus Limertinib as First-line Treatment for NSCLC.' on May 13.

Brief Summary: A prospective, controlled Phase II clinical study on the efficacy and safety of the combination of limertinib and bevacizumab versus limertinib monotherapy as first - line treatment for locally advanced or recurrent metastatic non - squamous NSCLC with EGFR mutations and high PD-L1 expression.

Study Start Date: June 30

Study Type: INTERVENTIONAL

Condition: EGFR Mutation Positive Advanced Non Small Cell Lung Cancer PD-L1 Positive

Intervention: DRUG: Limertini...